查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1791666

全球内视镜逆行性造影市场

Endoscopic Retrograde Cholangiopancreatography
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球内视镜逆行性造影市场规模将达 75 亿美元

全球内视镜逆行性造影市场规模预计在2024年达到47亿美元，预计在2024-2030年的分析期间内将以8.3%的复合年增长率成长，到2030年将达到75亿美元。内视镜检查是本报告分析的细分市场之一，预计其复合年增长率将达到9.6%，到分析期末将达到29亿美元。内视镜治疗设备细分市场在分析期间的复合年增长率预计为8.7%。

美国市场预计将达到 12 亿美元，中国市场复合年增长率将达到 8.0%

美国视镜逆行性胰造影市场规模预计2024年达到12亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到12亿美元，在2024-2030年的分析期间内，复合年增长率为8.0%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为7.8%和6.9%。在欧洲，预计德国市场的复合年增长率约为6.5%。

全球内视镜逆行性造影(ERCP) 市场 - 主要趋势与驱动因素摘要

为什么 ERCP 是胃肠病学和肝胆胰疾病中的一个重要程序？

内视镜逆行性胰造影(ERCP) 是一种微创内视镜技术，用于诊断和治疗胆道及胰臟疾病，包括胆结石、胆管狭窄、胰臟肿瘤和慢性胰臟炎。此技术结合内视镜和萤光透视技术，可观察并治疗胆道和胰管疾病，从而减少开放性手术的需求。

胆囊疾病、胰臟癌和胆管阻塞的发生率不断上升，加上老化人口更容易罹患肝胆疾病，这些因素显着增加了对内视镜逆行性胰胆管摄影 (ERCP) 的需求。此外，ERCP 配件（例如自膨式金属支架 (SEMS)、括约肌切开器和球囊扩张器）的进步，正在提高手术成功率和患者预后。随着医院和专科胃肠病中心内视镜检查能力的提升，ERCP 的应用预计将进一步成长。

ERCP 技术有哪些最新创新？

内视镜逆行性胰胆管摄影 (ERCP) 的最新进展着重于增强视觉化效果、减少併发症并提高治疗精准度。高清数位透视和人工智慧辅助造影造影解读技术的进步，提高了对小病变和胆管异常的检测率。我们先进的胆管镜平台 SpyGlass 直接可视化系统能够即时成像胆管和胰管，从而实现有针对性的切片检查采集和精准引导取石。

生物分解性胆道支架的引入减少了再次手术的需求，提高了患者的便利性，并降低了医疗成本。此外，机器人辅助内视镜逆行性胰胆管摄影 (ERCP) 技术正在研究中，以提高手术准确性，减少操作人员疲劳，并改善复杂胆道和胰臟疾病的治疗效果。随着 ERCP 技术的不断发展，基于机器学习的预测分析与人工智慧引导的内视镜导航的整合有望提高该手术的准确性和安全性。

推动 ERCP 市场成长的因素有哪些？

内视镜逆行性胰胆管摄影 (ERCP) 市场的成长动力源自于胃肠道疾病发病率的上升、微创技术的日益普及以及内视镜成像和介入工具的进步。胆道和胰臟疾病患者对非手术治疗的日益偏好，加上先进内视镜中心的扩张，共同推动了市场需求。此外，胰臟癌发生率的上升以及对治疗性内视镜手术需求的不断增长，也促进了 ERCP 的普及。

下一代 ERCP 设备、人工智慧胆道镜平台以及机器人辅助内视镜整合的监管批准预计将进一步加速市场成长。持续的技术进步、不断增加的医疗保健投资以及全球专科胃肠病学护理服务的普及，预计将推动 ERCP 市场在未来几年大幅扩张。

部分

产品（内视镜、内视镜治疗设备、视觉化系统、能量设备等）；程序（胆道括约肌切开术、胆道支架置入术、胆道扩张术、胰臟括约肌切开术、胰管支架置入术、胰管扩张术）；最终用户（医院、门诊病人设施）

受访公司范例

  • Ambu A/S
  • Ambu Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bio-Rad Medisys Pvt. Ltd.
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical
  • DCC Healthcare（Medi-Globe GmbH）
  • Fujifilm Holdings Corporation
  • HOBBS MEDICAL
  • HOYA Corporation
  • Huger Medical Instrument Co., Ltd
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Lancetinc Medical
  • LeoMed
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP30780

Global Endoscopic Retrograde Cholangiopancreatography Market to Reach US$7.5 Billion by 2030

The global market for Endoscopic Retrograde Cholangiopancreatography estimated at US$4.7 Billion in the year 2024, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Endoscopes, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Endotherapy Devices segment is estimated at 8.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.0% CAGR

The Endoscopic Retrograde Cholangiopancreatography market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market - Key Trends & Drivers Summarized

Why Is ERCP a Critical Procedure in Gastrointestinal and Hepatobiliary Medicine?

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a minimally invasive endoscopic technique used for the diagnosis and treatment of biliary and pancreatic disorders, including gallstones, bile duct strictures, pancreatic tumors, and chronic pancreatitis. This procedure combines endoscopy and fluoroscopy to visualize and treat conditions affecting the biliary and pancreatic ducts, reducing the need for open surgical interventions.

The rising prevalence of gallbladder disease, pancreatic cancer, and bile duct obstructions, along with increasing geriatric populations prone to hepatobiliary disorders, has significantly increased the demand for ERCP procedures. Additionally, advancements in ERCP accessories, including self-expanding metal stents (SEMS), sphincterotomes, and balloon dilators, have improved procedural success rates and patient outcomes. As hospitals and specialty gastroenterology centers expand their endoscopic capabilities, ERCP adoption is expected to grow further.

What Are the Latest Innovations in ERCP Technology?

Recent advancements in ERCP have focused on enhancing visualization, reducing complications, and improving therapeutic precision. The development of high-definition digital fluoroscopy and AI-assisted cholangiography interpretation has improved the detection of small lesions and bile duct abnormalities. SpyGlass Direct Visualization Systems, a state-of-the-art cholangioscopy platform, allows real-time imaging of bile and pancreatic ducts, enabling targeted biopsy collection and precision-guided stone removal.

The introduction of biodegradable biliary stents has reduced the need for repeat procedures, improving patient convenience and lowering healthcare costs. Additionally, robot-assisted ERCP techniques are being explored to enhance procedural precision, reduce operator fatigue, and improve outcomes in complex biliary and pancreatic disorders. As ERCP continues to evolve, the integration of machine learning-based predictive analytics and AI-guided endoscopic navigation is expected to enhance procedural accuracy and safety.

What Is Driving the Growth of the ERCP Market?

The growth in the ERCP market is driven by rising gastrointestinal disorders, increased adoption of minimally invasive techniques, and advancements in endoscopic imaging and intervention tools. The growing preference for non-surgical treatments for biliary and pancreatic diseases, combined with the expansion of advanced endoscopy centers, has fueled market demand. Additionally, the rise in pancreatic cancer incidence and the increasing need for therapeutic endoscopic procedures have contributed to ERCP adoption.

Regulatory approvals for next-generation ERCP devices, AI-powered cholangioscopy platforms, and the integration of robotic-assisted endoscopy are expected to further accelerate market growth. With continued technological advancements, rising healthcare investments, and increasing global access to specialized gastroenterology care, the ERCP market is poised for substantial expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Endoscopic Retrograde Cholangiopancreatography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, Others); Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation); End-Use (Hospitals, Outpatient Facilities)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Ambu A/S
  • Ambu Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bio-Rad Medisys Pvt. Ltd.
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical
  • DCC Healthcare (Medi-Globe GmbH)
  • Fujifilm Holdings Corporation
  • HOBBS MEDICAL
  • HOYA Corporation
  • Huger Medical Instrument Co., Ltd
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Lancetinc Medical
  • LeoMed
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Endoscopic Retrograde Cholangiopancreatography - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Pancreatic and Biliary Disorders Drives Demand for ERCP Procedures Globally
    • Advancements in ERCP Devices Enhance Procedural Accuracy and Reduce Complication Rates
    • Aging Population and Gallstone-Related Complications Fuel Volume Growth in ERCP Interventions
    • Integration of Fluoroscopy and Digital Imaging Tools Supports Complex ERCP Navigation and Diagnosis
    • Availability of Disposable Duodenoscopes Addresses Contamination Risks and Improves Infection Control
    • Increase in Minimally Invasive Biliary Drainage Techniques Expands Use of ERCP in Non-Surgical Settings
    • Specialty Training Programs and GI Fellowship Expansion Promote Adoption of Advanced ERCP Procedures
    • Growth in Therapeutic ERCP for Stent Placement and Stone Extraction Strengthens Hospital Utilization
    • Hybrid Endoscopic Procedures Combine ERCP With EUS for Improved Visualization and Targeting
    • Coding and Reimbursement Updates Enhance Procedural Profitability for Outpatient ERCP Settings
    • Development of Smart Guidewires and Cannulation Devices Increases Success Rate in Complex ERCP
    • Global Expansion of Endoscopy Suites and Digestive Health Centers Fuels ERCP Procedure Adoption
    • Portable Imaging and AI-Guided ERCP Platforms Enable Better Access in Community and Rural Hospitals
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Endoscopic Retrograde Cholangiopancreatography Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Endoscopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Endoscopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Endotherapy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Endotherapy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Visualization Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Visualization Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Energy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Energy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pancreatic Duct Stenting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pancreatic Duct Stenting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pancreatic Duct Dilation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pancreatic Duct Dilation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Biliary Sphincterotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Biliary Sphincterotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biliary Stenting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Biliary Stenting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Biliary Dilatation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Biliary Dilatation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pancreatic Sphincterotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Pancreatic Sphincterotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Outpatient Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Outpatient Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • JAPAN
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • CHINA
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • EUROPE
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • FRANCE
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • GERMANY
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • UNITED KINGDOM
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030

IV. COMPETITION